RecruitingPhase 2NCT06015022

EGCG for Hepatocellular Carcinoma Chemoprevention

Phase II Randomized Controlled Trial of Epigallocatechin Gallate for Hepatocellular Carcinoma Chemoprevention


Sponsor

University of Texas Southwestern Medical Center

Enrollment

60 participants

Start Date

Sep 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This phase II trial tests epigallocatechin gallate (EGCG) for its efficacy and safety in preventing development of hepatocellular carcinoma (HCC) in patients with liver cirrhosis.


Eligibility

Min Age: 18 Years

Inclusion Criteria10

  • Adults (≥ 18 years-old)
  • Clinically and/or histologically diagnosed cirrhosis
  • No active hepatic decompensation
  • No prior history of HCC
  • Adequate hematologic, hepatic, and renal function
  • Karnofsky performance status score ≥70
  • Both sexes and all racial/ethnic groups will be considered
  • FIB-4 index \> 3.25
  • High-risk PLSec at baseline
  • Absence of HLA-B\*35:01

Exclusion Criteria6

  • Prior or ongoing use of EGCG
  • History of adverse reaction to green tea products
  • Severe obesity (BMI \> 40 kg/m2)
  • Active drinking
  • EGCG treatment \<4 weeks or \<80% of planned regimen at the end of week 4
  • HCC development during the study

Interventions

DRUGEpigallocatechin gallate (EGCG)

EGCG is a green tea-derived catechin

OTHERPlacebo

Placebo in the same capsule with the experimental agent (EGCG).


Locations(1)

UT Southwestern

Dallas, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06015022


Related Trials